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Abstract
Background: The rationale of using bovine papillomavirus-1 (BPV-1) derived vectors in gene
therapy protocols lies in their episomal maintenance at intermediate to high copy number, and
stable, high-level expression of the gene products. We constructed the BPV-1 based vector
harbouring the human low-density lipoprotein receptor (LDLR) gene cDNA and tested its ability
to restore the function of the LDLR in the receptor-deficient cell line CHO-ldlA7.
Results: The introduced vector p3.7LDL produced functionally active LDL receptors in the
receptor-deficient cell line CHO-ldlA7 during the 32-week period of observation as determined by
the internalisation assay with the labelled LDL particles.
Conclusion: Bovine papillomavirus type-1 (BPV-1)-derived vectors could be suitable for gene
therapy due to their episomal maintenance at intermediate to high copy number and stable, high-
level expression of the gene products. The constructed BPV-1 based vector p3.7LDL produced
functionally active LDL receptors in the LDLR-deficient cell line CHO-ldlA7 during the 32-week
period of observation.
In vivo experiments should reveal, whether 1–5% transfection efficiency obtained in the current
work is sufficient to bring about detectable and clinically significant lowering of the amount of
circulating LDL cholesterol particles.
Background
The low-density lipoprotein receptor (LDLR) is an integral
membrane glycoprotein that specifically binds LDL parti-
cles and mediates cholesterol homeostasis through recep-
tor-mediated endocytosis. Mutations in the LDLR gene
give rise to an inherited autosomal disease familial hyper-
cholesterolemia (FH). The incidence of the homozygous
form of FH is 1:106, whereas the heterozygous form af-
fects 1 in 500 individuals [1]. Correction of homozygous
FH is possible in several ways including liver transplanta-
tion [2], LDL apheresis [3] and plasmapheresis [4]. These
treatments are laborious and in the case of liver transplan-
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tation contain several risks. Hepatocytes naturally express
LDLR protein at a high level and thus are the most prom-
ising target for the LDLR gene transfer. Ex vivo and in vivo
approaches have been used in liver-directed gene therapy.
The ex vivo method was used in the first human LDLR
gene therapy trial [5]. The in vivo introduction of the nor-
mal LDLR gene into receptor-deficient cells should poten-
tially result in clinically beneficial effects using less
invasive procedures. Several protocols for liver-directed
gene transfer have been used, e.g., those based on retrovi-
rus [6], adenovirus [7–9] and adeno-associated virus
(AAV) [10]. Retroviral vectors have widely been used in ex
vivo gene therapy protocols to correct liver diseases,
whereas in vivo gene therapy has been achieved after the
liver cells have been stimulated to regenerate. One major
limitation to the usage of retroviral vectors is their inabil-
ity to infect non-dividing cells [11]. Recombinant adeno-
viruses can infect non-dividing cells with high efficiency
and are rapidly concentrated in the liver after systemic ad-
ministration. However, there are obstacles to the clinical
application of these vectors as they have limited life span
within the cell, and host antiviral immune response re-
duces the duration of vector persistence and precludes
long-term transgene expression by repeated injection of
the vector [12]. AAV is another popular vector, but the low
titre of pure virus preparation is the major hurdle for its
broader application [13]. The rationale of using the BPV-
1-derived vectors in gene therapy protocols lies in their ep-
isomal maintenance at intermediate to high copy number
and stable, high-level expression of the gene products. It
has been shown that transforming proteins E5, E6 and E7
are not required whereas E1 and E2 are essential and suf-
ficient for BPV-1 replication [14].
Ohe et al. [15] have demonstrated that a BPV-1-based ex-
pression vector B45-Neo containing only E1, E2, a replica-
tion origin and an upstream regulatory region (URR).
They have demonstrated that episomal maintenance is re-
tained in this vector and that cDNA expression is compa-
rable to that of the parent construct that also contained
the transforming genes. The transforming activity of BPV-
1 for NIH-3T3 and C127 cells was ablated in the vector,
presumably through elimination of E5, E6, and E7. The
expression of cloned gene products in B45-Neo was main-
tained at high level for prolonged periods of time even
without selective pressure.
In the current study we have constructed a BPV-1 based
vector harbouring the human low-density lipoprotein re-
ceptor (hLDLR) cDNA. We demonstrate expression of the
hLDLR gene and functionality of its protein product, LDL
receptor in the LDLR-deficient cell line CHO-ldlA7.
Results and discussion
A recombinant BPV-1 based vector (Fig. 1) containing the
human low-density lipoprotein receptor (hLDLR) 2.6 kb
cDNA fragment under the transcriptional control of the
RSV long terminal repeat (LTR) promoter was construct-
ed. The vector also contains the BPV-1 genes E1, E2, the
replication origin and an upstream regulatory region
(URR), all required for essential and sufficient replication
of BPV-1 (14). The transforming genes E5, E6 and E7 were
deleted. The construct was named p3.7LDL.
First, the ability of the constructed vector to replicate in
the CHO cell line was tested. Moderate levels of replica-
tion were detected in the transient replication assay (Fig.
2). Further, the CHO cells that carry a defect in their en-
dogenous LDLR gene (CHO-ldlA7) [17] were transfected
with the vector. Absence of the hLDLR cDNA sequences in
the native CHOldlA7 genome and presence of the
p3.7LDL after transfection into CHO-ldlA7 cells was veri-
fied by PCR (data not shown) and Southern blot analysis
(Fig. 3). In all five transfected clones analysed, the tran-
script from the introduced LDLR gene was detected by RT-
PCR (Fig. 5) whereas there was no detectable LDLR RNA
in the native CHO-ldlA7 cells. The same results were ob-
tained with the Northern blot analysis (data not shown).
Figure 1
p3.7LDL – a bovine papillomavirus-1 (BPV-1) derived vector
harbouring the 2.6 kb hLDLR cDNA fragment.BMC Molecular Biology 2002, 3 http://www.biomedcentral.com/1471-2199/3/5
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We observed that apart from the episomal maintenance,
the vector had probably also integrated into the host cell
genome, judged by multiple bands on the Southern blot.
On the other hand, the multiple bands could also reflect
concatemerisation of the vector. It has been documented
clearly that papillomavirus episomes tend to form episo-
mal concatemers during the long term maintenance (24).
On the gels such long concatemers may co-migrate with
the chromosomal DNA and leave impression of integrat-
ed plasmid DNA.
Integration of the p3.7LDL sequences was further con-
firmed by FISH (Fig. 4a). The sequence of the expression
vector integrated into the genome gives cross-hybridisa-
tion signals represented by yellow double dots on the
metaphase chromosomes. The speckled appearance of the
vector signal indicates the episomal maintenance of the
introduced vector. No such signals were observed in the
FISH analysis of native CHO-ldlA7 cells (Fig. 4b). The
possibility of integration of the BPV-1 based vectors in
some cell lines has been also demonstrated by Ohe et al.
[15]. However, the mechanism of integration has not
been clearly defined yet. Next, we looked for presence of
the LDLR protein in transfected receptor-deficient cells by
immunofluorescence assay (Fig. 6). The protein-specific
fluorescent signal was present in 1–5% of the examined
cells, localising mainly in the Golgi complex area, where
post-translational processing of the protein occurs; the
signal was also observed to be evenly associated with the
cell membrane (Fig. 6a) while native CHO-ldlA7 cells dis-
played only faint background fluorescent signal (Fig. 6b).
To determine the functional properties of the transgene
LDLR we studied its ability to internalise LDL particles.
The DiI-labeled LDL particles were added into the culture
medium of transfected and native CHO-ldlA7 cells. After
three hours of incubation and fixation, the transfected
cells displayed a strong signal inside the cell, attributable
to the internalisation of the labelled particles (Fig. 7).
Several vector systems for treatment of the LDLR defect
have been used to date, but all of them have their limits.
Adenoviral vectors have been used in receptor-deficient
animal models for transduction of the LDLR cDNA into
the liver [9,19]. In the trials to reduce plasma LDL level in
receptor-deficient (Watanabe) rabbits via recombinant
adenovirus vector-mediated gene transfer, the LDL-lower-
ing effect lasted for 4–6 days [19]. The transient nature of
reduction of plasma LDL concentrations is due to the im-
mune response mounted against the recombinant adeno-
viral vector. The LDLR deficient mice give both humoral
and cellular immune responses specific for the therapeutic
transgene product [20,21]. Retrovirus vectors have also
been used to target the LDLR gene to liver cells in mice.
Since less than 0.2% of the hepatocytes in normal condi-
tions are in the replication cycle and retroviruses can in-
fect proliferating cells only, hepatocyte proliferation
needs to be stimulated either by partial liver resection
alone, or in combination with thymidine kinase/gancy-
clovir treatment [6]. The need for repeated retrovirus in-
jections via portal vein catheter and obvious hazard of
permanent liver damage sets limits to the usage of this
type of vector in humans. Bovine papillomavirus type-1
Figure 2
Transient replicative properties of the expression vectors.
CHO cells were electroporated with 1, 2 and 5 µg of
p3.7LDL (lanes 2,3,4) and the empty self-replicating vector
TK3.7 (lanes 6, 7 8). Low-molecular weight DNA was
digested with DpnI and the linearising enzyme Bpu1102I.
Fragments were analysed by Southern blotting. The corre-
sponding marker DNAs (200 pg each) were digested with
Bpu1102I (lanes 1 and 5). Hybridisation probe was a 1 kb
BPV-1 origin fragment. Exposure 12 hrs.
Figure 3
The Southern blot analysis of native and the p3.7LDL-trans-
fected CHO-ldlA7 cell clones. Lanes 1 to 5 – Bpu1102
digested genomic DNA from different transfected cell clones;
lane 6-Bpu1102 digested genomic DNA from native CHO-
ldlA7 cells; lane 7-positive control-the Bpu 1102 linearised
p3.7LDL, which gives rise to a 19.3 kb band. The same line-
arised vector was used as a hybridisation probe. Multiple
bands in transfected clones suggest integration of the vector
sequences into the host cell genome.BMC Molecular Biology 2002, 3 http://www.biomedcentral.com/1471-2199/3/5
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(BPV-1)-derived vectors could be suitable for gene therapy
due to their episomal maintenance at intermediate to
high copy number and stable, high-level expression of
gene products. The transforming proteins E5, E6 and E7
are not required while E1 and E2 are essential and suffi-
cient for the BPV-1 replication [14]. It has been noticed
that human papillomavirus E1 and E2 proteins have very
low immunogenicity [22], which may allow repeated in-
troduction of the papilloma virus-based vectors contain-
ing therapeutic genes into individuals.
Of course, it can not be ruled out that the viral sequences
present in the vector elicit immune response in vivo in hu-
mans, however in the DNA vaccination experiments
where E2 expression cassette was used in the plasmid, we
were unable to detect any induction of antibodies against
the BPV1 E2 protein in mice (DNA was delivered intra-
muscularly by needle injection or by Gene Gun delivery of
DNA-coated gold particles). Induction of humoral re-
sponse against the E1 protein has been complicated, be-
cause expression of E1 is taking place at too low a level. It
might be perfectly possible that immune response is sub-
dued due to the low level of E1. Induction of cellular im-
mune response has been studied also in the E2 protein
DNA vaccination experiments. T-cell proliferation assay
gave clearly negative results. Simultaneous expression of
other antigens from the same plasmid (HIV1 Nef protein)
at the same time showed strong induction of antigen-spe-
cific humoral and cellular immune response (our unpub-
lished results). Additional support for low
immunogenecity of E1 and E2 proteins comes from the
fact that latent infection of humans and animals with pap-
illomaviruses is quite common. In the case of strong im-
munosuppression caused by e.g. cancer chemotherapy or
by the HIV1 infection induces fast appearance of warts in
these patients.
The BPV-1 based expression vector p3.7LDL constructed
by us harbours the 2.6 kb human low-density lipoprotein
(hLDLR) cDNA fragment. After transfection of the con-
struct to the LDLR-deficient cell line CHO-ldlA7 the cells
produced hLDLR mRNA and expressed the hLDLR protein
during a 32-week period of observation. This is consider-
ably longer time range than with the popular adenoviral
vector systems (approximately 4–6 days). The long-term
episomal maintenance of the bovine papillomavirus type-
1 plasmids has been documented earlier (18). The trans-
fected cells were able to internalise DiI-labelled LDL par-
ticles as judged by the internalisation assay.
Figure 4
Figure 4a. Fluorescence in situ analysis of the p3.7LDL-trans-
fected CHO-ldlA7 cells. The probe, generated from the
p3.7LDL gives cross-hybridisation signals represented by yel-
low double dots on chromosomes stained with propidium
iodide. This can be explained by integration of the vector
sequences into the host cell genome The discrete yellow
dots dispersed all over the chromosomes also correspond to
plasmid-specific signals and suggest the presence of an episo-
mal vector.
Figure 4b. Fluorescence in situ analysis of the native CHO-
ldlA7 cells (negative control).
Figure 5
RT-PCR analysis of the native and the p3.7LDL-transfected
CHO-ldlA7 cell clones. Lanes 1 to 5 – RT-PCR products
from different transfected cell clones; lane 6 – native CHO-
ldlA7 cells; lane 7 – negative control for cDNA synthesis
(without RNA); lane 8 – negative control for PCR (reaction
without cDNA); lane 9–100 bp DNA ladder (Fermentas).BMC Molecular Biology 2002, 3 http://www.biomedcentral.com/1471-2199/3/5
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The transfection efficiency with the CHOldlA7 cell line
was 1–5%. It has been shown in the animal model system
that an 2–4% increase in the LDLR expression results in
20–30% decrease in the serum cholesterol (23). Further in
vivo experiments with the vector (we do not plan to use
viral constructs) should demonstrate whether the trans-
fection efficiency obtained by us is sufficient in terms of
physiological and clinical effects.
Conclusion
Bovine papillomavirus type-1 (BPV-1)-derived vectors
could be suitable for gene therapy due to their episomal
maintenance at intermediate to high copy number and
stable, high-level expression of the gene products. We
constructed the BPV-1 based vector p3.7LDL harboring
the human low-density lipoprotein receptor (LDLR) gene
cDNA. The construct produced functionally active LDL re-
ceptors in the LDLR-deficient cell line CHO-ldlA7 during
the 32-week period of observation.
In vivo experiments should reveal, whether the 1–5%
transfection efficiency obtained in the current work is suf-
ficient to bring about detectable and clinically significant
lowering of the amount of circulating LDL cholesterol par-
ticles.
Materials and methods
Vector manipulations
A plasmid pLDLR-3 (generously provided by Dr. K. Kon-
tula, Helsinki University) containing the whole hLDLR
cDNA was cut with XbaI/XhoI and a 2.6 kb fragment con-
taining the hLDLR cDNA without its 3'-untranslated re-
gion was isolated. This fragment was cloned into
pUE83(Xba-) to introduce BPV-1 origin and RSV LTR up-
streamof the ATG codon of the hLDLR cDNA and β -glob-
in poly(A) signal to the 3' end of the hLDLR cDNA. The
HindIII fragment of this construct was cloned into an ex-
Figure 6
Immunofluorescence-based detection of the LDLR protein in
the p3.7LDL-transfected and the native CHO-ldlA7 cells.
Supernatant of IgG2b monoclonal antibody (CRL-1691,
ATCC) against hLDLR was used as the primary and anti-
sheep FITC conjugated as the secondary antibody. Samples
were treated with SlowFade™ Light Antifade reagent and
viewed under a fluorescence microscope. In transfected cells,
the fluorescent signal is detectable in the cytoplasm generally
and in the Golgi complex particularly. A weak background
signal is visible in the native cell population
Figure 7
Assessment of the LDL receptor functionality by the inter-
nalisation assay. The p3.7LDL-transfected (A) and the native
(B) CHOldlA7 cells were incubated with DiI-LDL particles
and after fixation viewed by fluorescence microscopy. Signal
from the particles (seen as red spots) is visible inside the
transfected cells. Some non-transfected cells have labelled
particles associated with cell membranes.BMC Molecular Biology 2002, 3 http://www.biomedcentral.com/1471-2199/3/5
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pression vector p3.7 containing BPV-1 URR, E1, E2 and
the neomycine gene for selection. The construct was called
p3.7LDL.
Transient replication assay
CHO cells were electroporated with 1, 2 and 5 µg of the
empty self-replicating vector TK3.7 and the p3.7LDL.
Low-molecular weight DNA was harvested 72 hours post-
transfection and digested with DpnI and the linearising
enzyme Bpu1102I. Corresponding marker DNAs (200 pg)
were linearised with Bpu1102I. Fragments were analysed
by Southern blotting. The hybridisation probe was a BPV-
1 replication origin fragment.
Cell line and transfection
Chinese hamster ovary (CHO) ldlA7 cells were used as the
LDLR-deficient cell line. The cells were cultured in F12
medium with 10% fetal calf serum at 37°C in 5% CO2. 2.5
and 10 µg of the p3.7LDL was electroporated into 70–
80% confluent plate of CHO-ldlA7 cells at 230 V, using an
electroporation apparatus (Bio-Rad) at the capacitance
setting 960 µF. Twenty-four hours after transfection, G418
(500 µg/ml) was added to the medium for selection. Five
single colonies were picked in 12 days and analysed for
presence of the cloned sequence.
Recombinant DNA techniques and analysis of RNA
DNA manipulations were performed essentially as de-
scribed by Sambrook et al. [16]. Presence of the p3.7LDL
in transfected CHO-ldlA7 cells was verified by PCR and
Southern blot analysis. Native (non-transfected) CHO-
ldlA7 cells were used for control.
Primer pairs used in PCR: 3' end (ex17F-GAGGAGCAG-
CAGAAGGAAAGGG; ex17R-GGCAAATGTGGACCT-
CATCC); RSV LTR region/5' end (RSV5'LTR-
GCCTAGCTCGATACAATAAACGCC; ex3R-
CGACAGCCTTGCTCGTCTG). In the Southern blot anal-
ysis, 20 µg of DNA isolated from 1 native and 5 transfect-
ed CHOldlA7 cell clones was cut with Bpu1102I. The
Bpu1102I-linearized p3.7LDL was used as the hybridisa-
tion probe. The same linear vector was used as a control
probe on the gel.
Total cellular RNA was isolated from native and transfect-
ed CHO-ldlA7 cells with RNAzol™ B (WAK-Chemie Med-
ical). 20 µg of total cellular RNA was blotted onto nylon
transfer membrane (Hybond-N+) and hybridised with the
[32P]-labelled PCR product (exon 13–15) from the hLD-
LR.
In the RT-PCR, the 3' reverse primer (ex17R) was used to
synthesise the LDLR cDNA from 5 µg of total DNase-treat-
ed cellular RNA and a 200 bp region from the hLDLR gene
was amplified. Negative controls for the cDNA synthesis
(without RNA) and the PCR (reaction without cDNA)
were included in the assay.
Immunofluorescence assay
Transfected and native CHO-ldlA7 cells, grown in cover-
slip bottom dishes were washed with PBS, fixed in meth-
anol for 5 min (-20°C), permeabilised with 0.1% Triton
X-100, blocked in 1.5% dry milk in PBS-0.1%-Tween 20
and incubated separately with antibodies for one hour at
37°C. Supernatant of IgG2b monoclonal antibody (CRL-
1691, ATCC) against hLDLR was used as primary and
anti-sheep FITC conjugated (Sigma) as secondary anti-
body. Between every step, the coverslips were washed with
PBS-0.1%-Tween 20. Samples were treated with Slow-
Fade™ Light Antifade reagent (Molecular Probes) and then
viewed under a fluorescence microscope (Olympus AH-
2).
Internalisation assay
Transfected and native CHO-ldlA7 cells grown in cover-
slip bottom dishes were incubated in F12 medium con-
taining 10 µg/ml DiI-LDL particles (Molecular Probes) at
37°C for 3 hours. At the end of incubation, cells were
washed three times with PBS and fixed in 2% formalde-
hyde in PBS for 2 minutes. After fixation, cells were
washed and placed in PBS for viewing. Fluorescence imag-
es were obtained using a microscope (Olympus AH-2)
with a filter set for DiI (excitation 555 nm, emission 571
nm).
Fluorescence in situ hybridisation (FISH)
Metaphase spreads from transfected and native CHO-
ldlA7 cells were prepared by standard protocols. The cells
were synchronised in the medium containing 5-bromode-
oxyuridine (200 µg/ml) and released by adding thymi-
dine (0.3 µg/ml). FISH was performed with biotin-16-
dUTP probes by nick translation (Biotin-nick translation
mix, Boehringer Mannheim). The hybridisation mixture
contained 20 ng of the labelled probe with 10-fold excess
of herring sperm DNA in 50% formamide/10% dextran
sulfate/2× SSC. Detection of the hybridised probe was per-
formed using avidin-FITC and amplified once with addi-
tional layers of biotinylated goat antiavidin (both Vector
Laboratories) and avidin-FITC. DNA was counterstained
with 1 µg/ml propidium iodide and stained with 3 µg/ml
DAPI (4'-6'-diamidino-2-phenylindole). Slides were
mounted in antifade medium (Vectashield Vector) and
examined with Olympus AH-2 microscope.
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